nav-left cat-right
cat-right

The NCI is offering $20M to projects that move can...

The National Cancer Institute (NCI) faces a growing data problem. As the scale of its projects grows–one initiative is expected to generate 2.5 petabytes of data–downloading results for analysis on local systems becomes impractical. Recognizing this, the NCI has allocated $20 million for cloud-based genomics pilot projects. Having spent last year gathering feedback on what users want from cloud-based cancer...

Body kills ‘spontaneous’ blood cancers...

Immune cells undergo ‘spontaneous’ changes on a daily basis that could lead to cancers if not for the diligent surveillance of our immune system, Melbourne scientists have found. The research team from the Walter and Eliza Hall Institute found that the immune system was responsible for eliminating potentially cancerous immune B cells in their early stages, before they developed into B-cell lymphomas (also known as...

Popular blood type diet debunked

Researchers from the University of Toronto (U of T) have found that the theory behind the popular blood type diet–which claims an individual’s nutritional needs vary by blood type–is not valid. The findings are published in PLoS One. “Based on the data of 1,455 study participants, we found no evidence to support the ‘blood-type’ diet theory,” said the senior author of the study, Dr....

Stomaching stress

CAMBRIDGE, Mass.—Scientists at the Massachusetts Institute of Technology have discovered that ghrelin, known as the “hunger hormone,” plays a pivotal role in the widespread issue of posttraumatic stress disorder (PTSD), with recent research suggesting it could have the potential to prevent or treat the condition. Ghrelin is a relatively ‘young’ hormone, first discovered in the early 90s. It is constantly produced...

Biogen Idec, Proteostasis forge neurodegenerative ...

CAMBRIDGE, Mass.—Alzheimer’s disease, and some of its neurodegenerative cousins, came under fire from a new direction as Proteostasis Therapeutics Inc. this month brought in the R&D and clinical firepower of fellow Cambridge-based company Biogen Idec. in a worldwide collaboration agreement. The deal combines Proteostasis Therapeutics’ proprietary scientific platform and preclinical work on protein degradation with...

J&J gambles $12.5M in rare Big Pharma bet on ...

Later this week a little biotech named Capricor Therapeutics is set to begin a Phase II study of its new stem cell therapy with about $20 million in support from the California Institute for Regenerative Medicine (CIRM). And this morning Johnson & Johnson ($JNJ) is stepping up with a $12.5 million upfront to buy itself an option and a front-row seat on the program–marking a rare Big Pharma gamble on a field that is...
Page 29 of 153« First...1020...2728293031...405060...Last »